The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.
See here for further details on the change. Please also see our June 23, 2020 article for a summary of notable changes in the revised draft Guidelines.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
PMPRB consults further on revised proposed practice directions
The Patented Medicine Prices Review Board (PMPRB) holds public hearings on two types of mattersRead More -
Health Canada takes action to address generic drug submission review backlog
Health Canada is not currently meeting its performance standards for the review of some generic drug submissions. On September 1, 2026, Health Canada launched a new webpage, Improving how we review ge...Read More -
PMPRB releases September 2026 NEWSletter
The September NEWSletter also provides information about the PMPRB’s participation in past and future events, as well as NPDUIS research initiative and activities.Read More
